A Study to Compare Subcutaneous (SC) Versus Intravenous (IV) Administration of Herceptin (Trastuzumab) in Women With Human Epidermal Growth Factor Receptor (HER) 2-Positive Early Breast Cancer
Status: COMPLETED
Study type: INTERVENTIONAL
Conditions: Breast Cancer
Interventions: DRUG: 5-Fluorouracil|DRUG: Cyclophosphamide|DRUG: Docetaxel|DRUG: Epirubicin|DRUG: Herceptin IV [trastuzumab]|DRUG: Herceptin SC [trastuzumab]
Sponsor: Hoffmann-La Roche